Summit Therapeutics heads into the week with a genuinely mixed picture: short sellers are trimming exposure, options traders are the most bullish they have been in months, yet the clinical story underpinning the thesis remains unresolved and the next data readout is still roughly three months away. The clearest signal this week is in options. Calls are dominating flow in an unusual…
SMMT upgrades to Buy from Hold; Jefferies raises PT 67% to $25 vs. $17.28 close.
Key data as of 9 Nov 2026
Summit Therapeutics heads into its June 10 earnings report with its own executives making a conspicuous case for the stock just days before the release. On June 4, CEO Maky Zanganeh purchased 100,000 shares at $14.60 —…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SMMT — free to start on ORTEX.
Sign up for free →Open SMMT on ORTEX